Diabetic Macular Edema Market Size and Revenue Forecast to 2031

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " Diabetic Macular Edema Market - (By Drug Type (Anti-VEGF (Ranibizumab (Lucentis), Aflibercept (Eylea)), Corticosteroid Therapies (Dexamethasone (Ozurdex), Fluocinolone Acetonide (Iluvien)), Others), By Form (Intravitreal Injections, Intravitreal Implants), By Distribution Channel (Hospitals, Specialty Clinics, Mail Order Pharmacies)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Diabetic Macular Edema Market is valued at US$ 3.95 billion in 2023, and it is expected to reach US$ 4.56 billion by 2031, with a CAGR of 1.9% during the forecast period of 2024-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2895

Diabetic Macular Edema (DME) is a condition characterized by damage to the retina's small blood vessels, leading to swelling or fluid accumulation in the macula. The disease typically progresses gradually and may remain asymptomatic in its early stages. With increasing concerns regarding the health of diabetic patients, the demand for treatments addressing DME is expected to rise in the coming years. Key growth drivers include the increasing adoption of therapies such as aflibercept, bevacizumab, and ranibizumab, which are anticipated to significantly contribute to the expansion of the global DME market.

Moreover, the rising focus on research and development (R&D) in the healthcare sector, coupled with increasing disposable income, is expected to create substantial growth opportunities for market participants. Significant investments from major industry players, along with advancements in the development of various treatment solutions, have generated attractive revenue prospects for manufacturers and suppliers of DME therapies. Additionally, supportive government initiatives aimed at enhancing treatment accessibility and increasing awareness about DME and its management are expected to further stimulate market growth.

List of Prominent Players in the Diabetic Macular Edema Market:
• Novartis AG
• Bayer AG
• Allergen Plc.
• F. Hoffmann-La Roche Ltd.
• Alimera Sciences Inc.
• Valeant Pharmaceuticals International, Inc.
• KalVista Pharmaceuticals
• Genentech
• Oxurion
• Ocugen, Inc
• Regeneron Pharmaceuticals, Inc.
• Clearside Biomedical
• Daiichi Sankyo
• Arctic Vision
• Chugai Pharmaceutical Co., Ltd.
• Sanofi
• Novartis AG
• Sun Pharmaceutical Industries Ltd.
• Aurobindo Pharma
• Lupin
• Allergan
• Merck & Co., Inc.
• Pfizer Inc.
• GlaxoSmithKline plc
• IRIDEX Corporation

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-03

Market Dynamics
Drivers:
The increasing prevalence of diabetes and advancements in treatment options are key factors anticipated to drive the growth of the global Diabetic Macular Edema (DME) market. The rising demand for DME therapies among diabetic patients is expected to contribute significantly to the overall market revenue. Furthermore, expanding research and development (R&D) activities focused on improving DME treatments are projected to further stimulate market growth.

Challenges:
A major challenge facing the DME market is the lack of awareness and a shortage of skilled healthcare professionals in developing regions, which is expected to restrain market growth. Additionally, the high cost associated with DME treatments remains a significant barrier to market expansion. The COVID-19 pandemic has also had a notable impact on the industry, causing disruptions in global supply chains and resulting in substantial economic losses for key market participants. Distributors, suppliers, and retailers have struggled to move inventory, while manufacturers have faced production halts due to lockdown measures and social distancing protocols.

Regional Trends:
North America is expected to hold a dominant share of the global DME market in terms of revenue and is projected to grow at a significant compound annual growth rate (CAGR) over the forecast period. This growth is attributed to the rising number of diabetic patients and increased R&D efforts by leading companies. Similarly, Europe has secured a substantial market share, driven by its strong economic infrastructure and increasing adoption of advanced DME treatments. The implementation of innovative strategies by key stakeholders, coupled with increased collaboration among leading market players to strengthen regional market presence, is expected to create favorable opportunities for market expansion.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2895

Segmentation of Diabetic Macular Edema Market-
By Drug Type-
• Anti-VEGF
o Ranibizumab (Lucentis)
o Aflibercept (Eylea)
• Corticosteroid Therapies
o Dexamethasone (Ozurdex)
o Fluocinolone Acetonide (Iluvien)
• Others
By Form-
• Intravitreal Injections
• Intravitreal Implants
By Distribution Channel-
• Hospitals
• Specialty Clinics
• Mail Order Pharmacies
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.